<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.340">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>cns-tumors</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
</style>


<script src="cns-tumors_files/libs/clipboard/clipboard.min.js"></script>
<script src="cns-tumors_files/libs/quarto-html/quarto.js"></script>
<script src="cns-tumors_files/libs/quarto-html/popper.min.js"></script>
<script src="cns-tumors_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="cns-tumors_files/libs/quarto-html/anchor.min.js"></script>
<link href="cns-tumors_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="cns-tumors_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="cns-tumors_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="cns-tumors_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="cns-tumors_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">



<p><img src="img%5CCNS-Tumors0.jpg" class="img-fluid"></p>
<section id="central-nervous-system-tumors" class="level1">
<h1>Central Nervous System Tumors</h1>
</section>
<section id="serdar-balci-md" class="level1">
<h1>Serdar BALCI, MD</h1>
</section>
<section id="cns-tumors" class="level1">
<h1>CNS Tumors</h1>
<ul>
<li><strong>Annual incidence of CNS tumors</strong>
<ul>
<li><strong>10-17/100,000 persons intracranial tumors</strong></li>
<li><strong>1-2/100,000 persons for intraspinal tumors</strong></li>
</ul></li>
<li><strong>1/2-2/3 primary tumors</strong></li>
<li><strong>Rest are metastatic</strong></li>
<li><strong>20% of all pediatric tumors</strong>
<ul>
<li><strong>likely to arise in the posterior fossa</strong></li>
<li><strong>in adults, mostly supratentorial</strong></li>
</ul></li>
</ul>
</section>
<section id="characteristics-of-cns-tumors" class="level1">
<h1>Characteristics of CNS tumors</h1>
<ul>
<li><strong>Do not have detectable premalignant or in situ stages like carcinomas</strong></li>
<li><strong>Low-grade lesions may infiltrate large regions of the brain</strong>
<ul>
<li><strong>serious clinical deficits, nonresectability, and poor prognosis</strong></li>
</ul></li>
<li><strong>Anatomic site of the neoplasm influence outcome independent of histologic classification</strong>
<ul>
<li><strong>local mass effects</strong>
<ul>
<li><strong>benign meningioma may cause cardiorespiratory arrest from compression of the medulla</strong></li>
</ul></li>
<li><strong>Nonresectability</strong>
<ul>
<li><strong>brain stem gliomas</strong></li>
</ul></li>
</ul></li>
<li><strong>Even the most highly malignant gliomas rarely spread outside of the CNS</strong>
<ul>
<li><strong>Local infiltration</strong></li>
<li><strong>Spread in subarachnoid space</strong></li>
</ul></li>
</ul>
</section>
<section id="cns-tumors-1" class="level1">
<h1>CNS Tumors</h1>
<ul>
<li><strong>Tumors of the CNS may arise from</strong></li>
<li><strong>Cells of the coverings</strong>
<ul>
<li><strong>meningiomas</strong></li>
</ul></li>
<li><strong>The brain</strong>
<ul>
<li><strong>gliomas, neuronal tumors, choroid plexus tumors</strong></li>
</ul></li>
<li><strong>Other CNS cell populations</strong>
<ul>
<li><strong>primary CNS lymphoma, germ cell tumors</strong></li>
</ul></li>
<li><strong>Elsewhere in the body</strong>
<ul>
<li><strong>metastases</strong></li>
</ul></li>
</ul>
</section>
<section id="classification-of-cns-tumors" class="level1">
<h1>Classification of CNS Tumors</h1>
<p><img src="img%5CCNS-Tumors1.jpg" class="img-fluid"></p>
</section>
<section id="cell-of-origin-based-classification" class="level1">
<h1>Cell of Origin based classification</h1>
<p><img src="img%5CCNS-Tumors2.png" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors3.png" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors4.png" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors5.png" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors6.png" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors7.png" class="img-fluid"></p>
</section>
<section id="the-most-important-feature-for-differential-diagnosis" class="level1">
<h1>The most important feature for differential diagnosis</h1>
<p><strong>Localization, localization, localization …</strong></p>
<p><strong>Age</strong></p>
<p><strong>Radiologic features</strong></p>
<p><strong>Histomorphologic features</strong></p>
<p><strong>Genetic features</strong></p>
</section>
<section id="localisation-of-cns-tumors" class="level1">
<h1>Localisation of CNS tumors</h1>
<ul>
<li><strong>Distinct types of tumors affect specific brain regions</strong>
<ul>
<li><strong>Cerebellum → medulloblastoma</strong></li>
<li><strong>Intraventricular location → Central neurocytoma</strong></li>
</ul></li>
<li><strong>Specific age populations</strong>
<ul>
<li><strong>Pediatric age → medulloblastoma, pilocytic astrocytomas</strong></li>
<li><strong>Older patients → glioblastoma, lymphoma</strong></li>
</ul></li>
</ul>
</section>
<section id="spread-of-cns-tumors" class="level1">
<h1>Spread of CNS tumors</h1>
<p><strong>Metastatic spread of brain tumors to other regions of the body is rare</strong></p>
<p><strong>Spinal subarachnoid tumor seeding</strong></p>
<p><img src="img%5CCNS-Tumors8.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="grading-of-cns-tumors" class="level1">
<h1>Grading of CNS tumors</h1>
<p><strong>Grading is based on histological subtype</strong></p>
<p><strong>Grade I tumors</strong></p>
<p><strong>Grade II tumors</strong></p>
<p><strong>Grade III tumors</strong></p>
<p><strong>Grade IV tumors</strong></p>
<p><strong>Benign, Resection is cure</strong></p>
<p><strong>Progression can be seen</strong></p>
</section>
<section id="gliomas" class="level1">
<h1>GLIOMAS</h1>
</section>
<section id="gliomas-1" class="level1">
<h1>Gliomas</h1>
<ul>
<li><strong>Tumors of the brain parenchyma</strong></li>
<li><strong>Resemblance to different types of glial cells</strong></li>
<li><strong>Types of glial tumors</strong>
<ul>
<li><strong>Astrocytomas</strong></li>
<li><strong>Oligodendrogliomas</strong></li>
<li><strong>Ependymomas</strong></li>
</ul></li>
<li><strong>Most common types are highly infiltrative or “diffuse gliomas”</strong>
<ul>
<li><strong>astrocytic, oligodendroglial, and mixed forms</strong></li>
</ul></li>
<li><strong>Ependymomas form solid masses</strong></li>
</ul>
</section>
<section id="grading-of-cns-gliomas" class="level1">
<h1>Grading of CNS gliomas</h1>
<p><strong>Increasing tumor malignancy is associated with more cytologic anaplasia, increased cell density, necrosis, and mitotic activity</strong></p>
<p><strong>Grade I tumors</strong></p>
<p><strong>Grade II tumors</strong></p>
<p><strong>Grade III tumors</strong></p>
<p><strong>Grade IV tumors</strong></p>
</section>
<section id="astrocytoma" class="level1">
<h1>Astrocytoma</h1>
<ul>
<li><strong>Pilocytic astrocytomas</strong>
<ul>
<li><strong>Grade I</strong></li>
</ul></li>
<li><strong>İnfiltrating gliomas</strong>
<ul>
<li><strong>Diffuse Astrocytoma, Grade II</strong>
<ul>
<li><strong>Atypical nuclear features</strong></li>
<li><strong>İnfiltration</strong></li>
</ul></li>
<li><strong>Anaplastic Astrocytoma, Grade III</strong>
<ul>
<li><strong>Increased mitosis</strong></li>
</ul></li>
<li><strong>Glioblastoma, Grade IV</strong>
<ul>
<li><strong>Necrosis</strong></li>
<li><strong>Microvascular (endothelial) proliferation</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="pilocytic-astrocytoma-grade-i" class="level1">
<h1>Pilocytic Astrocytoma, Grade I</h1>
<ul>
<li><strong>Benign tumor</strong></li>
<li><strong>Affecting children and young adults</strong></li>
<li><strong>Location</strong>
<ul>
<li><strong>Most commonly cerebellum</strong></li>
<li><strong>Third ventricle</strong></li>
<li><strong>Optic pathways</strong></li>
<li><strong>Spinal cord</strong></li>
<li><strong>Cerebral hemispheres</strong></li>
</ul></li>
<li><strong>Cyst associated with the tumor</strong>
<ul>
<li><strong>Symptomatic recurrence from incompletely resected lesions is often associated with cyst enlargement, rather than growth of the solid component</strong></li>
</ul></li>
<li><strong>Tumors of hypothalamus are especially problematic because they cannot be resected completely</strong></li>
</ul>
<p><img src="img%5CCNS-Tumors9.png" class="img-fluid"></p>
<p><strong>pilocytic astrocytoma</strong></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="pilocytic-astrocytoma" class="level1">
<h1>Pilocytic Astrocytoma</h1>
<ul>
<li><strong>Activating mutations in the serine-threonine kinase BRAF</strong>
<ul>
<li><strong>a partial tandem duplication event</strong></li>
<li><strong>point mutation (V600E)</strong></li>
</ul></li>
<li><strong>No mutation in IDH1 and IDH2</strong></li>
</ul>
<p><strong>Cystic</strong></p>
<p><strong>Mural nodule in the wall of the cyst</strong></p>
<p><strong>If solid, usually well circumscribed</strong></p>
<p><strong>Bipolar cells with long, thin “hairlike” processes</strong></p>
<p><strong>GFAP-positive</strong></p>
<p><strong>Rosenthal fibers, eosinophilic granular bodies, and microcysts are often present</strong></p>
<p><strong>Necrosis and mitoses are very rare</strong></p>
<p><img src="img%5CCNS-Tumors10.png" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors11.png" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors12.png" class="img-fluid"></p>
</section>
<section id="diffuse-astrocytomas" class="level1">
<h1>Diffuse Astrocytomas</h1>
<ul>
<li><strong>80% of adult gliomas</strong></li>
<li><strong>Fourth-sixth decades of life</strong></li>
<li><strong>Usually in the cerebral hemispheres</strong></li>
<li><strong>Presenting signs and symptoms</strong>
<ul>
<li><strong>Seizures</strong></li>
<li><strong>Headaches</strong></li>
<li><strong>focal neurologic deficits related to the anatomic site of involvement</strong></li>
</ul></li>
<li><strong>Spectrum of histologic differentiation that correlates well with clinical course and outcome</strong>
<ul>
<li><strong>well-differentiated astrocytoma (grade II/IV)</strong></li>
<li><strong>anaplastic astrocytoma (grade III/IV)</strong></li>
<li><strong>glioblastoma (grade IV/IV)</strong></li>
</ul></li>
</ul>
<p><strong>Infiltrating pontine glioma (astrocytoma)</strong></p>
<p><img src="img%5CCNS-Tumors13.png" class="img-fluid"></p>
<p>Autopsy Pathology: A Manual and Atlas</p>
<p><strong>Diffusely infiltrating astrocytoma</strong></p>
<p><img src="img%5CCNS-Tumors14.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><img src="img%5CCNS-Tumors15.png" class="img-fluid"></p>
<p><strong>Well-differentiated astrocytomas are poorly defined, gray, infiltrative tumors that expand and distort the invaded brain without forming a discrete mass</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CCNS-Tumors16.png" class="img-fluid"></p>
<p><strong>Infiltration beyond the grossly evident margins is always present</strong></p>
<p><strong>Cut surface of the tumor is either firm or soft and gelatinous</strong></p>
<p><strong>Cystic degeneration may be seen</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CCNS-Tumors17.png" class="img-fluid"></p>
<p><strong>Clinical Neuropathology Text and Color Atlas</strong></p>
<p><img src="img%5CCNS-Tumors18.png" class="img-fluid"></p>
<p><strong>Practical Surgical Neuropathology</strong></p>
<p><img src="img%5CCNS-Tumors19.png" class="img-fluid"></p>
<p><strong>Brain Tumor Pathol (2011) 28:177–183</strong></p>
<ul>
<li><strong>Well-differentiated astrocytomas can be static for several years</strong>
<ul>
<li><strong>When progress; the mean survival is more than 5 years</strong></li>
</ul></li>
<li><strong>Rapid clinical deterioration, correlates with the appearance of anaplastic features and more rapid tumor growth</strong></li>
<li><strong>Tumors increase in grade</strong>
<ul>
<li><strong>well-differentiated → anaplastic astrocytoma → glioblastoma</strong></li>
</ul></li>
<li><strong>Once the histologic features of glioblastoma appear, the prognosis is very poor</strong></li>
<li><strong>Resection, radiotherapy, and chemotherapy median survival is 15 months</strong></li>
</ul>
<p><img src="img%5CCNS-Tumors20.png" class="img-fluid"></p>
<p><strong>Brain Tumor Pathol (2011) 28:177–183</strong></p>
</section>
<section id="defects-in-tricyclic-carbon-cycle" class="level1">
<h1>Defects in tricyclic carbon cycle</h1>
<p><img src="img%5CCNS-Tumors21.png" class="img-fluid"></p>
<p><strong>Isocitrate dehydrogenase mutations cause accumulation of byproducts</strong></p>
<p><strong>Most important discovery in malignant CNS tumors</strong></p>
<p><strong>Cancer Cell. 2010 Jan 19;17(1):7-9</strong></p>
<p><img src="img%5CCNS-Tumors22.png" class="img-fluid"></p>
<p><strong>N Engl J Med 2009;360:765-73.</strong></p>
</section>
<section id="well-differentiated-astrocytomas" class="level1">
<h1>Well-differentiated astrocytomas</h1>
<p><strong>Mild to moderate increase in the number of glial cell nuclei</strong></p>
<p><strong>Variable nuclear pleomorphism</strong></p>
<p><strong>Intervening feltwork of fine, glial fibrillary acidic protein (GFAP)-positive astrocytic cell processes that give the background a fibrillary appearance</strong></p>
<p><strong>Transition between neoplastic and normal tissue is indistinct</strong></p>
<p><strong>Tumor cells can be seen infiltrating normal tissue many centimeters from the main lesion</strong></p>
</section>
<section id="anaplastic-astrocytomas-grade-iii" class="level1">
<h1>Anaplastic astrocytomas, Grade III</h1>
<p><strong>More densely cellular</strong></p>
<p><strong>Greater nuclear pleomorphism</strong></p>
<p><strong>Mitotic figures</strong></p>
<p><img src="img%5CCNS-Tumors23.png" class="img-fluid"></p>
<p><strong>Practical Surgical Neuropathology</strong></p>
</section>
<section id="glioblastoma-grade-iv" class="level1">
<h1>Glioblastoma, Grade IV</h1>
<p><strong>Loss-of-function mutations in the p53 and Rb tumor suppressor pathways</strong></p>
<p><strong>Gain-of-function mutations in the oncogenic PI3K pathways</strong></p>
<p><strong>Mutations that alter the enzymatic activity of two isoforms of the metabolic enzyme isocitrate dehydrogenase (IDH1 and IDH2) are common in lower-grade astrocytomas</strong></p>
<p><strong>Immunostaining for the mutated form of IDH1 has become an important diagnostic tool in evaluating biopsy specimens for the presence of low-grade astrocytoma</strong></p>
</section>
<section id="glioblastoma" class="level1">
<h1>Glioblastoma</h1>
<ul>
<li><strong>Appearance similar to that of anaplastic astrocytoma AND</strong></li>
<li><strong>Necrosis</strong>
<ul>
<li><strong>pseudopalisading nuclei</strong></li>
</ul></li>
<li><strong>Vascular proliferation</strong>
<ul>
<li><strong>Microvascular proliferation</strong></li>
<li><strong>Vascular endothelial proliferation</strong></li>
<li><strong>Glomeruloid vascular proliferation</strong></li>
</ul></li>
</ul>
<p><img src="img%5CCNS-Tumors24.png" class="img-fluid"></p>
<p><strong>Glioblastoma</strong></p>
<p><strong>Necrotic, hemorrhagic, infiltrating mass</strong></p>
<ul>
<li><strong>Variation in the gross appearance of the tumor from region to region is characteristic:</strong></li>
<li><strong>Firm and white</strong></li>
<li><strong>Soft and yellow</strong>
<ul>
<li><strong>Necrosis</strong></li>
</ul></li>
<li><strong>cystic degeneration and hemorrhage</strong></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Glioblastoma multiforme</strong></p>
<p><img src="img%5CCNS-Tumors25.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><img src="img%5CCNS-Tumors26.png" class="img-fluid"></p>
<p><strong>Glioblastoma</strong></p>
<p><strong>densely cellular tumor with necrosis and pseudopalisading of tumor cell nuclei</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CCNS-Tumors27.png" class="img-fluid"></p>
<p><strong>Clinical Neuropathology Text and Color Atlas</strong></p>
<p><img src="img%5CCNS-Tumors28.png" class="img-fluid"></p>
<p><strong>Practical Surgical Neuropathology</strong></p>
<p><img src="img%5CCNS-Tumors29.png" class="img-fluid"></p>
<p><strong>Practical Surgical Neuropathology</strong></p>
</section>
<section id="oligodendroglioma" class="level1">
<h1>OLIGODENDROGLIOMA</h1>
</section>
<section id="oligodendroglioma-1" class="level1">
<h1>Oligodendroglioma</h1>
<ul>
<li><strong>5-15% of gliomas</strong></li>
<li><strong>Fourth-fifth decades</strong></li>
<li><strong>Several years neurologic complaints, often seizures</strong></li>
<li><strong>Mostly in the cerebral hemispheres</strong>
<ul>
<li><strong>Frontal or temporal lobes</strong></li>
</ul></li>
</ul>
<p><img src="img%5CCNS-Tumors30.png" class="img-fluid"></p>
<p><strong>Oligodendroglioma tumor cells have round nuclei, often with a cytoplasmic halo</strong></p>
<p><strong>Blood vessels in the background are thin and can form an interlacing pattern</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>Better prognosis than that for patients with astrocytomas of similar grade</strong></li>
<li><strong>Treatment with surgery, chemotherapy, and radiotherapy yields</strong>
<ul>
<li><strong>average survival of 10-20 years, well-differentiated (WHO grade II)</strong></li>
<li><strong>5-10 years for anaplastic (WHO grade III) oligodendrogliomas</strong></li>
</ul></li>
</ul>
<p><strong>Deletions of chromosomes 1p and 19q</strong></p>
<p><strong>1p and 19q loss typically occur together</strong></p>
<p><strong>Tumors with deletions of 1p and 19q are usually highly responsive to chemotherapy and radiotherapy</strong></p>
<p><img src="img%5CCNS-Tumors31.png" class="img-fluid"></p>
</section>
<section id="well-differentiated-oligodendrogliomas-who-grade-iiiv" class="level1">
<h1>Well-differentiated oligodendrogliomas(WHO grade II/IV)</h1>
<ul>
<li><strong>Infiltrative tumors</strong></li>
<li><strong>Gelatinous, gray masses</strong></li>
<li><strong>May show cysts, focal hemorrhage, and calcification</strong></li>
<li><strong>Sheets of regular cells</strong>
<ul>
<li><strong>spherical nuclei containing finely granular-appearing chromatin (similar to that in normal oligodendrocytes)</strong></li>
<li><strong>surrounded by a clear halo of cytoplasm</strong></li>
</ul></li>
<li><strong>Delicate network of anastomosing capillaries</strong></li>
<li><strong>Calcification</strong>
<ul>
<li><strong>present in 90% of these tumors</strong></li>
<li><strong>ranges in extent from microscopic foci to massive depositions</strong></li>
</ul></li>
<li><strong>Mitotic activity usually is difficult to detect</strong></li>
</ul>
</section>
<section id="anaplastic-oligodendroglioma-who-grade-iiiiv" class="level1">
<h1>Anaplastic oligodendroglioma (WHO grade III/IV)</h1>
<p><strong>More aggressive subtype</strong></p>
<p><strong>Higher cell density</strong></p>
<p><strong>Nuclear anaplasia</strong></p>
<p><strong>Mitotic activity</strong></p>
</section>
<section id="ependymoma" class="level1">
<h1>EPENDYMOMA</h1>
</section>
<section id="ependymoma-1" class="level1">
<h1>Ependymoma</h1>
<ul>
<li><strong>Arise next to</strong>
<ul>
<li><strong>the ependyma-lined ventricular system</strong></li>
<li><strong>central canal of the spinal cord</strong></li>
</ul></li>
<li><strong>First 2 decades of life</strong>
<ul>
<li><strong>fourth ventricle</strong></li>
<li><strong>5-10% of the primary brain tumors in this age group</strong></li>
</ul></li>
<li><strong>Adults</strong>
<ul>
<li><strong>spinal cord is their most common location</strong></li>
<li><strong>frequent in the setting of neurofibromatosis type 2</strong></li>
</ul></li>
<li><strong>The clinical outcome for completely resected supratentorial and spinal ependymomas is better than for those in the posterior fossa</strong></li>
</ul>
<p><strong>Fourth ventricle</strong></p>
<p><strong>Solid or papillary masses</strong></p>
<p><strong>Extending from the ventricular floor</strong></p>
<p><img src="img%5CCNS-Tumors32.png" class="img-fluid"></p>
<ul>
<li><strong>Cells with regular, round to oval nuclei and abundant granular chromatin</strong></li>
<li><strong>Between the nuclei a variably dense fibrillary background</strong></li>
<li><strong>Round or elongated structures</strong>
<ul>
<li><strong>rosettes, canals</strong></li>
<li><strong>resemble the embryologic ependymal canal</strong></li>
</ul></li>
<li><strong>Long, delicate processes extending into a lumen</strong></li>
<li><strong>Perivascular pseudorosettes</strong>
<ul>
<li><strong>tumor cells are arranged around vessels with an intervening zone containing thin ependymal processes</strong></li>
</ul></li>
</ul>
</section>
<section id="anaplastic-ependymoma" class="level1">
<h1>Anaplastic ependymoma</h1>
<p><strong>Increased cell density</strong></p>
<p><strong>High mitotic rates</strong></p>
<p><strong>Necrosis</strong></p>
<p><strong>Less evident ependymal differentiation</strong></p>
<p><img src="img%5CCNS-Tumors33.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="neuronal-tumors" class="level1">
<h1>NEURONAL TUMORS</h1>
</section>
<section id="neuronal-tumors-1" class="level1">
<h1>Neuronal Tumors</h1>
</section>
<section id="central-neurocytoma" class="level1">
<h1>Central neurocytoma</h1>
<p><strong>Low-grade neoplasm</strong></p>
<p><strong>Within and adjacent to the ventricular system</strong></p>
<p><strong>Most commonly the lateral or third ventricles</strong></p>
<p><strong>Evenly spaced, round, uniform nuclei</strong></p>
<p><strong>Islands of neuropil</strong></p>
</section>
<section id="ganglioglioma" class="level1">
<h1>Ganglioglioma</h1>
<ul>
<li><strong>Manifest with seizures</strong></li>
<li><strong>Slow-growing</strong></li>
<li><strong>Mixed tumor</strong>
<ul>
<li><strong>glial elements</strong>
<ul>
<li><strong>low-grade astrocytoma</strong></li>
</ul></li>
<li><strong>mature-appearing neurons</strong></li>
</ul></li>
<li><strong>Glial component occasionally becomes anaplastic</strong>
<ul>
<li><strong>then progresses rapidly</strong></li>
</ul></li>
</ul>
</section>
<section id="dysembryoplastic-neuroepithelial-tumor-dnet" class="level1">
<h1>Dysembryoplastic neuroepithelial tumor (DNET)</h1>
<ul>
<li><strong>Low-grade childhood tumor</strong></li>
<li><strong>Grows slowly</strong></li>
<li><strong>Relatively good prognosis after resection</strong></li>
<li><strong>Often manifests as a seizure disorder</strong></li>
<li><strong>Typically located in the superficial temporal lobe</strong></li>
<li><strong>Consists of small round neuronal cells</strong>
<ul>
<li><strong>arranged in columns</strong></li>
<li><strong>around central cores of processes</strong></li>
</ul></li>
<li><strong>Typically form multiple discrete intracortical nodules</strong>
<ul>
<li><strong>myxoid background</strong></li>
</ul></li>
<li><strong>Well-differentiated “floating” neurons within pools of mucopolysaccharide-rich myxoid fluid</strong></li>
</ul>
</section>
<section id="embryonal-primitive-neoplasms" class="level1">
<h1>EMBRYONAL (PRIMITIVE) NEOPLASMS</h1>
</section>
<section id="embryonal-primitive-neoplasms-1" class="level1">
<h1>Embryonal (Primitive) Neoplasms</h1>
<ul>
<li><strong>Neuroectodermal origin</strong></li>
<li><strong>Primitive “small round cell” appearance</strong>
<ul>
<li><strong>reminiscent of normal progenitor cells encountered in the developing CNS</strong></li>
</ul></li>
<li><strong>Differentiation is often limited</strong></li>
<li><strong>May progress along multiple lineages</strong></li>
</ul>
</section>
<section id="medulloblastoma" class="level1">
<h1>Medulloblastoma</h1>
<ul>
<li><strong>Most common Embryonal (Primitive) Neoplasm</strong></li>
<li><strong>20% of pediatric brain tumors</strong></li>
<li><strong>Cerebellum</strong></li>
<li><strong>Neuronal and glial markers are nearly always expressed</strong></li>
<li><strong>Highly malignant</strong>
<ul>
<li><strong>Prognosis for untreated patients is dismal</strong></li>
<li><strong>Exquisitely radiosensitive</strong></li>
<li><strong>Total excision, chemotherapy, and irradiation, the 5-year survival rate may be as high as 75%</strong></li>
</ul></li>
<li><strong>Primitive neuroectodermal tumors (PNETs)</strong>
<ul>
<li><strong>Tumors of similar histologic type and a poor degree of differentiation elsewhere in the nervous system</strong></li>
</ul></li>
</ul>
<p><img src="img%5CCNS-Tumors34.png" class="img-fluid"></p>
<p><strong>Located in the midline of the cerebellum</strong></p>
<p><strong>Lateral tumors occur more often in adults</strong></p>
<p><strong>Often well circumscribed, gray, and friable</strong></p>
<p><strong>May extend to the surface of the cerebellar folia and involve the leptomeninges</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CCNS-Tumors35.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><img src="img%5CCNS-Tumors36.png" class="img-fluid"></p>
<p><strong>Extremely cellular</strong></p>
<p><strong>Sheets of anaplastic (small blue) cells</strong></p>
<p><strong>Small, with little cytoplasm</strong></p>
<p><strong>Hyperchromatic nuclei</strong></p>
<p><strong>Abundant mitosis</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CCNS-Tumors37.png" class="img-fluid"></p>
<p><strong>Focal neuronal differentiation</strong></p>
<p><strong>Homer Wright or neuroblastic rosette</strong></p>
<p><strong>Resembles the rosettes in neuroblastomas</strong></p>
<p><strong>Primitive tumor cells surrounding central neuropil</strong></p>
<p><strong>-delicate pink material formed by neuronal processes</strong></p>
</section>
<section id="genetic-of-medulloblastoma" class="level1">
<h1>Genetic of medulloblastoma</h1>
<ul>
<li><strong>Morphologically similar tumors commonly exhibit distinct alterations</strong></li>
<li><strong>There is a relationship between the underlying mutations and outcome</strong></li>
<li><strong>MYC amplification</strong>
<ul>
<li><strong>associated with poor outcomes</strong></li>
</ul></li>
<li><strong>WNT signaling pathway</strong>
<ul>
<li><strong>have a more favorable course</strong></li>
</ul></li>
<li><strong>Sonic hedgehog (shh) pathway</strong>
<ul>
<li><strong>has a critical role in tumorigenesis but an uncertain relationship to outcome</strong></li>
</ul></li>
</ul>
</section>
<section id="lymphomas" class="level1">
<h1>LYMPHOMAS</h1>
</section>
<section id="primary-cns-lymphoma" class="level1">
<h1>Primary CNS Lymphoma</h1>
<ul>
<li><strong>Mostly diffuse large B cell lymphoma</strong></li>
<li><strong>2% of extranodal lymphomas</strong></li>
<li><strong>1% of intracranial tumors</strong></li>
<li><strong>Most common CNS neoplasm in immunosuppressed persons</strong>
<ul>
<li><strong>nearly always positive for the oncogenic Epstein-Barr virus</strong></li>
</ul></li>
<li><strong>Nonimmunosuppressed populations</strong>
<ul>
<li><strong>age spectrum is relatively wide</strong></li>
<li><strong>incidence increasing &gt;60 years of age</strong></li>
</ul></li>
<li><strong>Aggressive disease</strong>
<ul>
<li><strong>relatively poor response to chemotherapy compared with peripheral lymphomas</strong></li>
</ul></li>
<li><strong>Multiple tumor nodules within the brain parenchyma</strong></li>
<li><strong>Involvement outside of the CNS is an uncommon late complication</strong></li>
<li><strong>Lymphoma originating outside the CNS rarely spreads to the brain parenchyma</strong>
<ul>
<li><strong>when it happens, within the CSF or involvement of the meninges</strong></li>
</ul></li>
<li><strong>Often involve deep gray structures</strong></li>
<li><strong>Also white matter and the cortex</strong></li>
<li><strong>Periventricular spread is common</strong></li>
<li><strong>Relatively well defined as compared with glial neoplasms</strong>
<ul>
<li><strong>not as discrete as metastases</strong></li>
</ul></li>
<li><strong>EBV-associated tumors</strong>
<ul>
<li><strong>extensive areas of necrosis</strong></li>
</ul></li>
<li><strong>Nearly always aggressive large B-cell lymphomas</strong>
<ul>
<li><strong>rarely other histologic types</strong></li>
</ul></li>
<li><strong>Malignant cells accumulate around blood vessels</strong></li>
<li><strong>Infiltrate the surrounding brain parenchyma</strong></li>
</ul>
</section>
<section id="germ-cell-tumors" class="level1">
<h1>GERM CELL TUMORS</h1>
</section>
<section id="primary-brain-germ-cell-tumors" class="level1">
<h1>Primary brain germ cell tumors</h1>
<ul>
<li><strong>Occur along the midline</strong>
<ul>
<li><strong>Most commonly in the pineal and the suprasellar regions</strong></li>
</ul></li>
<li><strong>0.2-1% of brain tumors in European</strong></li>
<li><strong>10% of brain tumors in Japanese</strong></li>
<li><strong>Young</strong>
<ul>
<li><strong>90%, during the first 2 decades of life</strong></li>
</ul></li>
<li><strong>Pineal region show a strong male predominance</strong></li>
<li><strong>Germinoma</strong>
<ul>
<li><strong>Most common primary CNS germ cell tumor</strong></li>
<li><strong>resembles testicular seminoma</strong></li>
</ul></li>
<li><strong>Metastatic gonadal germ cell tumors also occur</strong></li>
</ul>
</section>
<section id="meningioma" class="level1">
<h1>MENINGIOMA</h1>
</section>
<section id="meningioma-1" class="level1">
<h1>Meningioma</h1>
<ul>
<li><strong>Predominantly benign tumors</strong></li>
<li><strong>Arise from arachnoid meningothelial cells</strong></li>
<li><strong>Usually occur in adults</strong></li>
<li><strong>Often attached to the dura</strong></li>
<li><strong>Found along any of the external surfaces of the brain</strong></li>
<li><strong>Within the ventricular system</strong>
<ul>
<li><strong>arise from the stromal arachnoid cells of the choroid plexus</strong></li>
</ul></li>
<li><strong>Sympotoms</strong>
<ul>
<li><strong>vague nonlocalizing symptoms</strong></li>
<li><strong>focal findings compression of adjacent brain</strong></li>
</ul></li>
<li><strong>Most meningiomas are easily separable from underlying brain</strong>
<ul>
<li><strong>some tumors infiltrate the brain</strong></li>
<li><strong>increased risk of recurrence</strong></li>
</ul></li>
<li><strong>Overall prognosis</strong>
<ul>
<li><strong>lesion size and location</strong></li>
<li><strong>surgical accessibility</strong></li>
<li><strong>histologic grade</strong></li>
</ul></li>
<li><strong>Neurofibromatosis type 2 (NF2)</strong>
<ul>
<li><strong>Multiple meningiomas</strong></li>
<li><strong>eighth-nerve schwannomas</strong></li>
<li><strong>glial tumors</strong></li>
</ul></li>
<li><strong>Half of meningiomas not associated with NF2</strong>
<ul>
<li><strong>acquired loss-of-function mutations in the NF2 TSG on 22q</strong></li>
</ul></li>
<li><strong>Mutations found in all grades of meningioma</strong>
<ul>
<li><strong>involved with tumor initiation</strong></li>
</ul></li>
<li><strong>Mutations in NF2 are more common in:</strong>
<ul>
<li><strong>fibroblastic, transitional, and psammomatous growth pattern</strong></li>
</ul></li>
</ul>
<p><img src="img%5CCNS-Tumors38.png" class="img-fluid"></p>
<p><strong>Meningioma</strong></p>
<p><strong>WHO grade I/IV</strong></p>
<p><strong>well-defined dura-based masses</strong></p>
<p><strong>compress the brain but do not invade it</strong></p>
<p><strong>Extension into the overlying bone may be present</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Parasagittal meningioma</strong></p>
<p><img src="img%5CCNS-Tumors39.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><strong>Intraosseous meningioma</strong></p>
<p><img src="img%5CCNS-Tumors40.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="histologic-patterns-of-meningioma" class="level1">
<h1>Histologic patterns of Meningioma</h1>
<ul>
<li><strong>Syncytial</strong>
<ul>
<li><strong>whorled clusters of cells without visible cell membranes that sit in tight groups</strong></li>
</ul></li>
<li><strong>Fibroblastic</strong>
<ul>
<li><strong>elongated cells and abundant collagen deposition between them</strong></li>
</ul></li>
<li><strong>Transitional</strong>
<ul>
<li><strong>shares features of the syncytial and fibroblastic types</strong></li>
</ul></li>
<li><strong>Psammomatous</strong>
<ul>
<li><strong>numerous psammoma bodies</strong></li>
</ul></li>
<li><strong>Secretory</strong>
<ul>
<li><strong>gland-like PAS-positive eosinophilic secretions known as pseudopsammoma bodies</strong></li>
</ul></li>
</ul>
<p><img src="img%5CCNS-Tumors41.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="atypical-meningiomas-who-grade-iiiv" class="level1">
<h1>Atypical meningiomas(WHO grade II/IV)</h1>
<p><strong>prominent nucleoli</strong></p>
<p><strong>increased cellularity</strong></p>
<p><strong>pattern-less growth</strong></p>
<p><strong>higher mitotic rate</strong></p>
<p><strong>More aggressive local growth</strong></p>
<p><strong>Higher rate of recurrence</strong></p>
<p><strong>Require therapy in addition to surgery</strong></p>
</section>
<section id="anaplastic-malignant-meningiomas-who-grade-iiiiv" class="level1">
<h1>Anaplastic (malignant) meningiomas(WHO grade III/IV)</h1>
<p><strong>Highly aggressive tumors</strong></p>
<p><strong>May resemble a high-grade sarcoma or carcinoma</strong></p>
<p><strong>usually some histologic evidence of a meningothelial cell origin</strong></p>
</section>
<section id="metastatic-tumors" class="level1">
<h1>METASTATIC TUMORS</h1>
</section>
<section id="metastatic-tumors-1" class="level1">
<h1>Metastatic Tumors</h1>
<p><strong>Mostly carcinomas</strong></p>
<p><strong>1/4-1/2 of intracranial tumors</strong></p>
<p><strong>Most common primary sites</strong></p>
<p><strong>Lung, breast, skin (melanoma), kidney, and gastrointestinal tract</strong></p>
<p><strong>Form sharply demarcated masses</strong></p>
<p><strong>Often at the gray-white junction, and elicit edema</strong></p>
<p><strong>The boundary between tumor and brain parenchyma is sharp at the microscopic level as well, with surrounding reactive gliosis</strong></p>
<p><strong>Direct and localized effects</strong></p>
</section>
<section id="section" class="level1">
<h1></h1>
<p><strong>Metastatic spread of brain tumors to other regions of the body is rare</strong></p>
<p><strong>Brain is not protected against spread of distant tumors</strong></p>
<p><strong>Carcinomas are the dominant type of systemic tumors that metastasize to the nervous system</strong></p>
<p><img src="img%5CCNS-Tumors42.png" class="img-fluid"></p>
<p><strong>Metastatic melanoma</strong></p>
<p><strong>Metastatic lesions are distinguished grossly from most primary central nervous system tumors by their multicentricity and well-demarcated margins</strong></p>
<p><strong>The dark color of the tumor nodules in this specimen is due to the presence of melanin</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="paraneoplastic-syndromes" class="level1">
<h1>Paraneoplastic syndromes</h1>
<ul>
<li><strong>Subacute cerebellar degeneration</strong>
<ul>
<li><strong>result in ataxia</strong></li>
<li><strong>destruction of Purkinje cells, gliosis, and a mild inflammatory infiltrate</strong></li>
</ul></li>
<li><strong>Limbic encephalitis</strong>
<ul>
<li><strong>subacute dementia</strong></li>
<li><strong>perivascular inflammatory cells, microglial nodules, some neuronal loss, and gliosis, all centered in the medial temporal lobe</strong></li>
</ul></li>
<li><strong>Subacute sensory neuropathy</strong>
<ul>
<li><strong>altered pain sensation</strong></li>
<li><strong>loss of sensory neurons from dorsal root ganglia, in association with inflammation</strong></li>
</ul></li>
<li><strong>Syndrome of rapid-onset psychosis, catatonia, epilepsy, and coma</strong>
<ul>
<li><strong>associated with ovarian teratoma</strong></li>
<li><strong>antibodies against the N-methyl-d-aspartate (NMDA) receptor</strong></li>
</ul></li>
</ul>
</section>
<section id="familial-tumor-syndromes" class="level1">
<h1>FAMILIAL TUMOR SYNDROMES</h1>
</section>
<section id="tuberous-sclerosis-tsc" class="level1">
<h1>Tuberous Sclerosis (TSC)</h1>
<ul>
<li><strong>Autosomal dominant</strong></li>
<li><strong>Development of hamartomas and benign neoplasms involving the brain and other tissues</strong></li>
<li><strong>CNS hamartomas</strong>
<ul>
<li><strong>cortical tubers</strong></li>
<li><strong>subependymal hamartomas</strong></li>
<li><strong>tumefactive form known as subependymal giant cell astrocytoma</strong></li>
</ul></li>
<li><strong>Proximity to the foramen of Monro</strong>
<ul>
<li><strong>present acutely with obstructive hydrocephalus</strong></li>
<li><strong>requires surgical intervention and/or therapy with an mTOR inhibitor</strong></li>
</ul></li>
<li><strong>Seizures</strong>
<ul>
<li><strong>associated with cortical tubers</strong></li>
<li><strong>difficult to control with antiepileptic drugs</strong></li>
</ul></li>
<li><strong>Extracerebral lesions</strong>
<ul>
<li><strong>renal angiomyolipomas</strong></li>
<li><strong>retinal glial hamartomas</strong></li>
<li><strong>pulmonary lymphangiomyomatosis</strong></li>
<li><strong>cardiac rhabdomyomas</strong></li>
<li><strong>Cysts</strong>
<ul>
<li><strong>liver, kidneys, and pancreas</strong></li>
</ul></li>
<li><strong>Cutaneous lesions</strong>
<ul>
<li><strong>angiofibromas, leathery thickenings in localized patches (shagreen patches), hypopigmented areas (ash leaf patches), and subungual fibromas</strong></li>
</ul></li>
</ul></li>
<li><strong>TSC1</strong>
<ul>
<li><strong>encodes hamartin</strong></li>
</ul></li>
<li><strong>TSC2</strong>
<ul>
<li><strong>encodes tuberin</strong></li>
</ul></li>
<li><strong>Two TSC proteins form a dimeric complex</strong>
<ul>
<li><strong>negatively regulates mTOR, a kinase that “senses” the cell’s nutrient status and regulates cellular metabolism</strong></li>
</ul></li>
<li><strong>Loss of either protein leads to increased mTOR activity</strong>
<ul>
<li><strong>Disrupts nutritional signaling and increases cell growth</strong></li>
</ul></li>
<li><strong>Cortical hamartomas</strong></li>
<li><strong>Firmer than normal cortex</strong></li>
<li><strong>Likened in appearance to potatoes</strong>
<ul>
<li><strong>“tubers”</strong></li>
</ul></li>
<li><strong>Composed of haphazardly arranged large neurons</strong></li>
<li><strong>Lack the normal cortical laminar architecture</strong></li>
<li><strong>Cells exhibit a mixture of glial and neuronal features</strong>
<ul>
<li><strong>large vesicular nuclei with nucleoli (like neurons)</strong></li>
<li><strong>abundant eosinophilic cytoplasm (like gemistocytic astrocytes)</strong></li>
<li><strong>Similar cells are present in the subependymal nodules</strong></li>
</ul></li>
</ul>
</section>
<section id="von-hippellindau-disease" class="level1">
<h1>von Hippel–Lindau Disease</h1>
<ul>
<li><strong>Autosomal dominant disorder</strong></li>
<li><strong>Hemangioblastoma</strong>
<ul>
<li><strong>cerebellar hemispheres, retina, and, less commonly, the brain stem, spinal cord, and nerve roots</strong></li>
</ul></li>
<li><strong>Cysts</strong>
<ul>
<li><strong>pancreas, liver, and kidneys</strong></li>
</ul></li>
<li><strong>Renal cell carcinoma</strong></li>
<li><strong>Frequency is 1/30,000-40,000</strong></li>
<li><strong>Therapy is directed at the symptomatic neoplasms</strong>
<ul>
<li><strong>surgical resection of cerebellar tumors and laser ablation of retinal tumors</strong></li>
</ul></li>
<li><strong>Tumor suppressor VHL</strong></li>
<li><strong>Encodes a protein that is part of a ubiquitin-ligase complex</strong></li>
<li><strong>Targets the transcription factor hypoxia-inducible factor (HIF) for degradation</strong></li>
<li><strong>Lost all VHL protein function</strong></li>
<li><strong>Express high levels of HIF</strong></li>
<li><strong>Expression of VEGF, various growth factors</strong></li>
<li><strong>Expression of erythropoietin</strong>
<ul>
<li><strong>paraneoplastic polycythemia</strong></li>
</ul></li>
<li><strong>Cerebellar capillary hemangioblastoma</strong>
<ul>
<li><strong>Highly vascular neoplasm</strong></li>
<li><strong>Mural nodule</strong></li>
<li><strong>Large, fluid-filled cyst</strong></li>
<li><strong>Numerous capillary-sized or somewhat larger thin-walled vessels</strong></li>
<li><strong>Intervening stromal cells with vacuolated, lightly PAS-positive, lipid-rich cytoplasm</strong></li>
</ul></li>
</ul>
<p><img src="img%5CCNS-Tumors43.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><img src="img%5CCNS-Tumors44.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><span style="color:#E72E09">Distribution of CNS Tumors</span></p>
<p><img src="img%5CCNS-Tumors45.jpg" class="img-fluid"></p>
<p><strong>A pilocytic astrocytoma of the cerebellum in a child. </strong></p>
<p><img src="img%5CCNS-Tumors46.jpg" class="img-fluid"></p>
<p><strong>Glioma of the brainstem – pilocytic astrocytoma</strong></p>
</section>
<section id="gbm.-note-the-prominent-vascularity-as-well-as-the-area-of-necrosis-at-the-left-with-neoplastic-cells-palisading-around-it-pseudopalisading-necrosis." class="level1">
<h1>GBM. Note the prominent vascularity as well as the area of necrosis at the left with neoplastic cells palisading around it (pseudopalisading necrosis*).</h1>
<p><img src="img%5CCNS-Tumors47.jpg" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors48.jpg" class="img-fluid"></p>
<p><img src="img%5CCNS-Tumors49.jpg" class="img-fluid"></p>
</section>
<section id="here-is-an-ependymoma-arising-from-the-ependymal-lining-of-the-fourth-ventricle-above-the-brainstem-and-bulging-toward-the-cerebellum." class="level1">
<h1>Here is an ependymoma arising from the ependymal lining of the fourth ventricle above the brainstem and bulging toward the cerebellum.</h1>
<p><img src="img%5CCNS-Tumors50.jpg" class="img-fluid"></p>
</section>
<section id="this-horizontal-ct-scan-section-of-the-brain-reveals-a-large-ependymoma-of-the-fourth-ventricle." class="level1">
<h1>This horizontal (CT scan) section of the brain reveals a large ependymoma of the fourth ventricle.</h1>
<p><img src="img%5CCNS-Tumors51.jpg" class="img-fluid"></p>
</section>
<section id="irregular-posterior-fossa-mass-medulloblastoma---near-the-midline-of-the-cerebellum-and-extending-into-the-fourth-ventricle-above-the-brainstem" class="level1">
<h1>Irregular posterior fossa mass (medulloblastoma) - near the midline of the cerebellum and extending into the fourth ventricle above the brainstem</h1>
</section>

</main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>